PATH | VRL
Menu

Safety and Immunogenicity of RTS,S/AS01 Malaria Vaccine in Infants and Children With WHO Stage 1 or 2 HIV Disease: A Randomised, Double-Blind, Controlled Trial

Malaria remains a major global public health concern, especially in sub-Saharan Africa. This article, published in The Lancet Infectious Diseases, reports the results of a study that aimed to assess the safety and immunogenicity of RTS,S/AS01 malaria vaccine in HIV-infected children. The authors found the vaccine to be well tolerated when given to children with World Health Organization clinical stage 1 or 2 HIV disease along with high antiretroviral and co-trimoxazole use. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Otieno L, Oneko M, Otieno W, et al.

Published: 2016

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Otieno L, Oneko M, Otieno W, et al. Safety and Immunogenicity of RTS,S/AS01 Malaria Vaccine in Infants and Children With WHO Stage 1 or 2 HIV Disease: A Randomised, Double-Blind, Controlled Trial. The Lancet Infectious Diseases2016;16(10):1134–1144.

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa